Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs

HAMILTON, Bermuda , April 08, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present preclinical data for KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor, at the Keystone Symposia, Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies, in Breckenridge, CO. Details of the presentation are as follows: KPL-404, a CD40 antagonist, blocked antigen-specific antibody responses in an in vivo NHP model and demonstrated strong PK/PD correlation (Poster # 2036) by Sujatha Muralidharan 1 , Brendan J. Classon 1 , Karalyne Crowder 2 , Andrea S.L. Wong 2 , Yoshinobu Yokota 2 , Florence Burleson 3 , Tracy Garron 1 , Moses Njenga 1 , John F. Paolini 1 will be presented during Poster Session 2 on Tuesday, April 9 th , 2019 at 7:30 p.m. Mountain Time in the Breckenridge Ballroom at the Beaver Run Resort . Kiniksa intends to make the materials available through the Investors and Media section of its website ( www.kiniksa.com ). About KPL-404 KPL-404 is an investigational humanized monoclonal antibody that is designed to inhibit the CD40-CD40-ligand interaction, a key T-cell co-stimulatory signal critical for B-cell maturation and immunoglobulin class switching. Dysregulation of the CD40-CD40L pathway has been implicated in multiple autoimmune disease pathologies such as Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren’s Syndrome and Grave’s Disease. About Kiniksa Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com . 1 Kiniksa Pharmaceuticals Corp. , MA, USA; 2 Altasciences Preclinical Seattle LLC , WA, USA; 3 Burleson Research Technologies Inc , NC, USA Every Second Counts!™ Kiniksa Investor and Media Contact Mark Ragosa (781) 430-8289 [email protected]

The release as fetched from its publisher. kiniksa.com ↗